These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2492477)

  • 1. Ascorbic acid metabolism and polyol pathway in diabetes.
    Yue DK; McLennan S; Fisher E; Heffernan S; Capogreco C; Ross GR; Turtle JR
    Diabetes; 1989 Feb; 38(2):257-61. PubMed ID: 2492477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the aldose reductase inhibitor tolrestat on nerve conduction velocity, Na/K ATPase activity, and polyols in red blood cells, sciatic nerve, kidney cortex, and kidney medulla of diabetic rats.
    Raccah D; Coste T; Cameron NE; Dufayet D; Vague P; Hohman TC
    J Diabetes Complications; 1998; 12(3):154-62. PubMed ID: 9618071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deficiency of ascorbic acid in experimental diabetes. Relationship with collagen and polyol pathway abnormalities.
    McLennan S; Yue DK; Fisher E; Capogreco C; Heffernan S; Ross GR; Turtle JR
    Diabetes; 1988 Mar; 37(3):359-61. PubMed ID: 2836250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue ascorbic acid and polyol pathway metabolism in experimental diabetes.
    Lindsay RM; Jamieson NS; Walker SA; McGuigan CC; Smith W; Baird JD
    Diabetologia; 1998 May; 41(5):516-23. PubMed ID: 9628267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyol pathway activity in nervous tissues of diabetic and galactose-fed rats: effect of dietary galactose withdrawal or tolrestat intervention therapy.
    Sredy J; Sawicki DR; Notvest RR
    J Diabet Complications; 1991; 5(1):42-7. PubMed ID: 1830318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion.
    McAuliffe AV; Brooks BA; Fisher EJ; Molyneaux LM; Yue DK
    Nephron; 1998 Nov; 80(3):277-84. PubMed ID: 9807036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of urinary albumin excretion in 6 month streptozocin-diabetic rats with the aldose reductase inhibitor tolrestat.
    McCaleb ML; Sredy J; Millen J; Ackerman DM; Dvornik D
    J Diabet Complications; 1988; 2(1):16-8. PubMed ID: 2968349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
    Cotter MA; Cameron NE; Hohman TC
    J Peripher Nerv Syst; 1998; 3(3):217-23. PubMed ID: 10959252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy.
    Finegold D; Lattimer SA; Nolle S; Bernstein M; Greene DA
    Diabetes; 1983 Nov; 32(11):988-92. PubMed ID: 6416910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil.
    Beyer-Mears A; Ku L; Cohen MP
    Diabetes; 1984 Jun; 33(6):604-7. PubMed ID: 6427041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of polyol-pathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats.
    Goldfarb S; Ziyadeh FN; Kern EF; Simmons DA
    Diabetes; 1991 Apr; 40(4):465-71. PubMed ID: 2010046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of neural myoinositol depletion in diabetic rats by aldose reductase inhibition with tolrestat.
    Kemper C; Dvornik D
    Proc Soc Exp Biol Med; 1986 Sep; 182(4):505-10. PubMed ID: 3090558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats.
    Schmidt RE; Plurad SB; Sherman WR; Williamson JR; Tilton RG
    Diabetes; 1989 May; 38(5):569-79. PubMed ID: 2497038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE; Cotter MA; Basso M; Hohman TC
    Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased nerve polyol levels in experimental diabetes and their reversal by Sorbinil.
    Whiting PH; Ross IS
    Br J Exp Pathol; 1988 Oct; 69(5):697-702. PubMed ID: 3143396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of Zopolrestat and Sorbinil on lens myo-inositol influx.
    Beyer-Mears A; Diecke FP; Mistry K; Cruz E
    Pharmacology; 1997 Feb; 54(2):76-83. PubMed ID: 9088040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does galactose feeding provide a valid model of consequences of exaggerated polyol-pathway flux in peripheral nerve in experimental diabetes?
    Willars GB; Lambourne JE; Tomlinson DR
    Diabetes; 1987 Dec; 36(12):1425-31. PubMed ID: 3678622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H; Tawata M; Aida K; Onaya T
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors.
    Tilton RG; Chang K; Pugliese G; Eades DM; Province MA; Sherman WR; Kilo C; Williamson JR
    Diabetes; 1989 Oct; 38(10):1258-70. PubMed ID: 2507378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of vanadate administration on polyol pathway in diabetic rat kidney.
    Saxena AK; Srivastava P; Kale RK; Baquer NZ
    Biochem Int; 1992 Feb; 26(1):59-68. PubMed ID: 1616498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.